earnings-spotlightNovartis $NVS Falls 9% on Third Trial Failure in One Week
Novartis just had the worst week in pharma since 2020. Three trial failures, a $12B acquisition that's looking like a dud, and analysts quietly giving up on the growth story.
2 min read
NVSAMGN